{'fraction_non_alphanumeric': 0.033860045146726865, 'fraction_numerical': 0.013544018058690745, 'mean_word_length': 5.290780141843972, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Production of bioactive rabbit antibodies against the mutated receptor peptide TSH-R-HIS17 and detection of hypertriiodothyroninemia in the rabbit.

We produced rabbit antibodies against mutated thyrotropin (TSH) receptor peptide TSH-R-HIS17 in comparison with non-mutated TSH receptor peptide TSH-R-ASP17. All the antibodies raised against TSH-R-HIS17 showed thyroid stimulating antibody (TSAb), thyroid stimulation blocking antibody (TSBAb) and/or TSH binding inhibiting immunoglobulin (TBII) activities and also those serum T3 levels were all in thyrotoxic levels associated with TSAb activities. However, all the antibodies raised against TSH-R-ASP17 had no activities of TSAb, TSBAb and/or TBII and those serum T3 levels were all within normal range. The data suggest that the mutation in the TSH receptor gene may have a possible relevance for the pathogenesis of Graves' disease.